ArticleFrontiers in cellular and infection microbiology2025
Comparative plasma metabolomics of Delta and Omicron SARS-CoV-2 variants: insights into variant-specific pathogenesis and therapeutic implications.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploratory comparison of PASC and SARS-CoV-2 infection through metabolomics and lipidomics in early pandemic and Omicron-era.Biochemistry and biophysics reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The emergence of SARS-CoV-2 led to a global pandemic. Delta and Omicron, classified as concerning variants, differ significantly in transmissibility, disease severity, and antibody neutralization. Delta is associated with more severe disease, whereas Omicron is linked to increased transmissibility yet milder disease. This study investigates plasma metabolomic differences between Delta and Omicron infections and their associations with disease severity and treatment response. Importantly, this work examines variant-specific treatment metabolic effects - an aspect that remains underexplored despite the ongoing evolution of SARS-CoV-2 variants - and thus begins to fill a critical gap in the literature. Methods: A total of 109 hospitalized SARS-CoV-2 patients, confirmed by RT-PCR positivity (53 Delta, 56 Omicron), were matched by age and sex. Plasma samples collected on hospitalization days 1, 2, and 7 were analyzed using DI/LC-MS/MS-based (direct injection, liquid chromatography-tandem mass-spectrometry) targeted metabolomics. We employed univariate and multivariate statistical and pathway analyses to investigate and characterize metabolomic differences. Results: Distinct metabolic profiles differentiated Delta and Omicron infections. Specific metabolites, including tyrosine, asparagine, leucine, and acylcarnitines (C3, C4, C5), significantly distinguished variants and severity groups. Delta infections showed higher associations with severe outcomes. Corticosteroid treatment influenced metabolic profiles, revealing associations with modulation of metabolic and clinical responses. Conclusion: This study reveals significant plasma-based metabolic differences between Delta and Omicron SARS-CoV-2 variants, potentially reflecting their distinct clinical outcomes and severities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.